Low dose of sodium-glucose transporter 2 inhibitor ipragliflozin attenuated renal dysfunction and interstitial fibrosis in adenine-induced chronic kidney disease in mice without diabetes

BACKGROUND: Sodium–glucose co-transporter 2 (SGLT2) inhibitor, a new class of glucose lowering agents, has been shown to be reno-protective in diabetes. OBJECTIVE: We aimed to explore whether SGLT2 inhibitor ipragliflozin has a direct reno-protective effect on non-diabetic chronic kidney disease (CK...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamato, Mayumi, Kato, Nao, Kakino, Ai, Yamada, Ken-ichi, Inoguchi, Toyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520892/
https://www.ncbi.nlm.nih.gov/pubmed/33015603
http://dx.doi.org/10.1016/j.metop.2020.100049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520892/
https://www.ncbi.nlm.nih.gov/pubmed/33015603
http://dx.doi.org/10.1016/j.metop.2020.100049

Ejemplares similares